|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...137138139140141142143144145146147...156157» |
- ||||| selurampanel (BGG492) / Novartis
New P2 trial: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - Jul 23, 2012
P2, N=145, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
New P3 trial: A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 23, 2012
P3, N=12, Active, not recruiting, Sponsor: Hoffmann-La Roche
- | New P1/2 trial: Green Tea Lozenges for the Management of Dry Mouth (clinicaltrials.gov) - Jul 22, 2012
P1/2, N=60, Recruiting, Sponsor: Georgia Regents University
- ||||| NN9828 / Novo Nordisk
New P2 trial: A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 19, 2012
P2, N=62, Completed, Sponsor: Novo Nordisk
- Enrollment change: Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=16, Completed, Sponsor: Yale University
N=20 --> 16
- Trial completion: Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=16, Completed, Sponsor: Yale University
N=20 --> 16 Not yet recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
New P4 trial, Retrospective data, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Jul 18, 2012
P4, N=1, Completed, Sponsor: Pfizer
- mavrilimumab (KPL-301) / Kiniksa
Trial initiation date: A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 18, 2012
P1, N=38, Completed, Sponsor: MedImmune Ltd
Not yet recruiting --> Completed Initiation date: Oct 2007 --> Oct 2008
- ||||| otelixizumab (ChAglyCD3) / GSK
Enrollment change: Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2 (clinicaltrials.gov) - Jul 18, 2012
P3, N=179, Completed, Sponsor: GlaxoSmithKline
Initiation date: Oct 2007 --> Oct 2008 N=396 --> 179
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
New P2 trial: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy (clinicaltrials.gov) - Jul 18, 2012
P2, N=274, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 17, 2012
P3, N=30, Completed, Sponsor: Hoffmann-La Roche
N=396 --> 179 Recruiting --> Completed
- Enrollment change, Glucose variability: Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability (clinicaltrials.gov) - Jul 16, 2012
P=N/A, N=35, Completed, Sponsor: University of Virginia
Recruiting --> Completed N=60 --> 35
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: ACT-RAY: A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment (clinicaltrials.gov) - Jul 16, 2012
P3, N=552, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=60 --> 35 Recruiting --> Active, not recruiting
- Trial completion, Glucose variability: Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability (clinicaltrials.gov) - Jul 16, 2012
P=N/A, N=35, Completed, Sponsor: University of Virginia
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- |||| otilimab (GSK3196165) / GSK
Trial completion: Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 15, 2012
P1/2, N=96, Completed, Sponsor: MorphoSys AG
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-TNF Agent (clinicaltrials.gov) - Jul 15, 2012
P=N/A, N=200, Recruiting, Sponsor: Hoffmann-La Roche
- Rituxan (rituximab) / Roche
Trial completion: A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis. (clinicaltrials.gov) - Jul 15, 2012
P2/3, N=50, Completed, Sponsor: University of South Florida
Active, not recruiting --> Completed Recruiting --> Completed
- || Enrollment closed: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Genetic Disease Investigators
Recruiting --> Completed Recruiting --> Active, not recruiting
- | adomeglivant (LY2409021) / Eli Lilly
New P1 trial: Study of LY2409021 in Participants With Type 1 Diabetes (clinicaltrials.gov) - Jul 12, 2012
P1, N=30, Completed, Sponsor: Eli Lilly and Company
- | Benlysta (belimumab) / GSK
Enrollment open, IO biomarker: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (clinicaltrials.gov) - Jul 11, 2012
P2, N=18, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Enrollment closed: A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=77, Active, not recruiting, Sponsor: Biomet, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Trial completion: JEMS: JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=2000, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- | Tavalisse (fostamatinib) / Rigel
New P2 trial: OSKIRA-Asia-1X: A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 11, 2012
P2, N=115, Terminated, Sponsor: AstraZeneca
- ||| sifalimumab (MDX-1103) / AstraZeneca
Trial initiation date: A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus (clinicaltrials.gov) - Jul 10, 2012
P2a, N=87, Completed, Sponsor: MedImmune LLC
Recruiting --> Completed Initiation date: May 2008 --> Aug 2008
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: DOSERA: Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA (clinicaltrials.gov) - Jul 10, 2012
P4, N=91, Completed, Sponsor: Pfizer
Initiation date: May 2008 --> Aug 2008 Active, not recruiting --> Completed
- | Biomarker, New P4 trial: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action (clinicaltrials.gov) - Jul 10, 2012
P4, N=200, Recruiting, Sponsor: Medical University of Vienna
- | New P1 trial: Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting (clinicaltrials.gov) - Jul 9, 2012
P1, N=20, Completed, Sponsor: Animas Corporation
- zoledronic acid / Generic mfg.
Trial termination: EXALT: Zoledronic Acid in MS-patients With Osteoporosis (clinicaltrials.gov) - Jul 8, 2012
P3, N=29, Terminated, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- ||||| fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate (clinicaltrials.gov) - Jul 8, 2012
P2, N=268, Active, not recruiting, Sponsor: Novo Nordisk
- | fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics (clinicaltrials.gov) - Jul 8, 2012
P2, N=268, Recruiting, Sponsor: Novo Nordisk A/S
- prednisone / Generic mfg.
Trial completion: The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy (clinicaltrials.gov) - Jul 8, 2012
P=N/A, N=30, Completed, Sponsor: Nanjing University School of Medicine
Active, not recruiting --> Terminated Recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia (clinicaltrials.gov) - Jul 8, 2012
P4, N=37, Completed, Sponsor: Michael Schiff, MD
Recruiting --> Completed N=102 --> 37
- | Plivensia (sirukumab) / J&J
New P1 trial: A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 8, 2012
P1, N=12, Completed, Sponsor: Janssen Research & Development, LLC
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment closed: Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults (clinicaltrials.gov) - Jul 8, 2012
P2, N=100, Active, not recruiting, Sponsor: Montefiore Medical Center
N=102 --> 37 Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia (clinicaltrials.gov) - Jul 8, 2012
P4, N=37, Completed, Sponsor: Michael Schiff, MD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- leflunomide / Generic mfg.
Enrollment change: A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications (clinicaltrials.gov) - Jul 5, 2012
P=N/A, N=1748, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed N=3496 --> 1748
- ||||| New P4 trial, Surgery: Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement Surgery (clinicaltrials.gov) - Jul 5, 2012
P4, N=250, Recruiting, Sponsor: DePuy International
- New P2 trial: Home Based Computer Gaming Hand Exercise Regimen for People With Arthritis Affecting the Hands (clinicaltrials.gov) - Jul 5, 2012
P2, N=30, Recruiting, Sponsor: University of Manitoba
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis (clinicaltrials.gov) - Jul 5, 2012
P3, N=69, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=3496 --> 1748 Active, not recruiting --> Completed
- ||| dalfampridine / Generic mfg.
Enrollment closed, HEOR: ENABLE: Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (clinicaltrials.gov) - Jul 4, 2012
P4, N=800, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date, Combination therapy, Monotherapy: An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment (clinicaltrials.gov) - Jul 4, 2012
P3, N=51, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Feb 2010 --> Feb 2011
- ||| Rituxan (rituximab) / Roche
Enrollment change: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. (clinicaltrials.gov) - Jul 4, 2012
P4, N=60, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Feb 2010 --> Feb 2011 N=100 --> 60
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy, Monotherapy: A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 4, 2012
P4, N=95, Completed, Sponsor: Hoffmann-La Roche
N=100 --> 60 Active, not recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: ACT-SURE: An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy (clinicaltrials.gov) - Jul 4, 2012
P3, N=926, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 4, 2012
P3, N=538, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | TRU-015 / Pfizer
Clinical: Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2012
P2, N=222, Terminated, Sponsor: Pfizer
Active, not recruiting --> Terminated; The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No safety reasons contributed to the termination of the study.
- Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical: Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jul 2, 2012
P=N/A, N=30, Recruiting, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- |||| Betaseron (IFN-β-1b) / Bayer
Trial completion: Betaseron Pregnancy Registry (clinicaltrials.gov) - Jul 1, 2012
P4, N=113, Completed, Sponsor: INC Research
No safety reasons contributed to the termination of the study. Active, not recruiting --> Completed
- Neo-Synephrine (phenylephrine hydrochloride ophthalmic solution) / Paragon BioTeck, Bausch Health, Akorn
Trial completion: DENDI: Endothelial Dysfunction and Diabetes (clinicaltrials.gov) - Jul 1, 2012
P=N/A, N=38, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Recruiting --> Completed
- | Benlysta (belimumab) / GSK
Enrollment change, IO biomarker: BELISS: Efficacy and Safety of Belimumab in Subjects With Primary Sj (clinicaltrials.gov) - Jun 30, 2012
P2, N=20, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed N=15 --> 20